Advanced Practice Provider
ARENSIA Exploratory Medicine GmbHHighlight
Summary
About the Role
About You
- Current unrestricted NP or PA license in Arizona
- Clinical research experience strongly preferred
- Strong understanding of Good Clinical Practice (GCP) and ICH guidelines
- Excellent clinical assessment and documentation skills including AEs
- Ability to read and interpret complex clinical trial protocols
- Strong leadership and team coordination skills
- Strong attention to detail
- Phase 2 exploratory medicine trial experience
- Familiarity with protocol deviation management and prevention
- Experience working with CRAs and pharmaceutical sponsors
- Experience in oncology or complex therapeutic areas
Benefits
- Competitive salary with comprehensive benefits including PTO and sick time
- Cutting-edge exploratory medicine research in oncology, rare diseases, and advanced therapies
- Opportunity for growth in a rapidly expanding clinic with future inpatient capabilities
- Collaborative research environment with experienced clinical investigators
- Professional development and continuing education opportunities
ARENSIA is a German operator of professional research clinics, dedicated to performing early-phase clinical trials - Phase IB, IIA, and PROOF OF CONCEPT - with novel compounds. Our trials involve a wide range of patient populations. ARENSIA clinics are designed to enable patient's access to innovative therapies early in the drug development process. Patients' safety and comfort are of paramount importance at ARENSIA. Our facilities are strategically located within or adjacent to large university/private hospitals in the following cities: Phoenix, Arizona USA, Bucharest and Cluj-Napoca in Romania, Chisinau in Moldova, Tbilisi in Georgia, Kyiv in Ukraine and Sofia in Bulgaria. Due to its dedicated research-oriented infrastructure, ARENSIA achieves a time reduction of avg. 60% through unrivaled recruiting performance vs. typical clinical trial sites which are overcrowded by daily hospital duties, lack of staff, competition for the same populations, and long timelines for contract negotiations. The shortened time and the different setup of concentrating effort on a few ARENSIA Clinics (instead of the traditional high number of sites) leads to an overall budget reduction of 50% for a typical Phase IB/IIA PROOF OF CONCEPT trial. 93% repeat business proves that ARENSIA’s value proposition is the long-expected disruptive breakthrough in time and cost! This has allowed our continuous growth while collaborating with the leading pharmaceutical companies worldwide, numerous biotechs, and global CROs.